You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The financing, led by Accelerated Digital Ventures, will go toward the development of 20 tests targeted at cancers and dementias.
The company expects the rollout of more reliable, user-friendly platforms will increase instrument usage among a substantial segment of its customer base.
When blood amyloid levels are combined with other risk factors, people with early Alzheimer's brain changes can be identified with high accuracy.
The firm will use the proceeds to continue developing its Proteograph platform, build its proteomic database, and develop liquid biopsy products for early disease detection.
The group will start a pilot study at Columbia University next week to sequence genes from 600 Parkinson's disease patients before expanding to a larger cohort.
Fulgent will use its Parkinson's disease NGS panel to target seven genes linked to the condition and generate curated reports for doctors and researchers.
Within the "Big Three" conditions, misdiagnoses related to stroke, sepsis, and lung cancer accounted for the most high-severity diagnostic error cases.
The Elisabeth Severance Prentiss Foundation gift will expand research into the use of saliva to monitor lithium levels in patients with bipolar and other disorders.
The firm is validating a mild TBI biomarker-based diagnostic kit for use by paramedics, first responders, and other healthcare professionals.
A combination of three biomarkers accurately predicted abnormal accumulation of beta-amyloid plaques in the brains of living Alzheimer's disease patients.
The new grant will be used to conduct whole-exome sequencing on 1,000 children participating in an autism spectrum disorder study for the purposes of biomarker development.
The guidelines provide recommendations for what CYP2C9 variant alleles should be included in clinical pharmacogenomic tests assessing that gene.
Abbott's test is designed to detect two proteins — GFAP and UCH-L1 — that are released from the brain into the bloodstream following brain injury.
Prescient will further the development and commercialization of the Infiniti Neural Response Panel to identify patients who may be at risk for opioid use disorder.
Evogen's protein biomarker-based test is designed to stratify actively seizing patients from those who have not experienced a recent seizure.
The biomarkers — ubiquitin carboxyl terminal hydrolase-L1 and glial fibrillary acidic protein — can be detected in blood soon after a brain injury.
The researchers developed a plasma protein signature that can identify patients with cerebrospinal fluid amyloid-β42 levels indicative of risk for the disease.
The Army previously awarded Abbott $11.3 million to develop a TBI test. Abbott has worked with DoD since 2014 to develop tests to help evaluate potential concussions.
Free genetic testing on a broad gene panel is available to children, from birth to five years old, if they've had an unprovoked seizure.
Companies are developing metabolomic tests both to aid in early diagnosis of the condition and to help guide treatment in patients with metabolic imbalances.